Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURAMORPH PF vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Morphine is a full opioid agonist that primarily acts on mu-opioid receptors in the central nervous system to produce analgesia, euphoria, and sedation. It also interacts with kappa and delta receptors. It inhibits ascending pain pathways and alters pain perception and response.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Management of moderate to severe pain when continuous opioid analgesia is needed for an extended period,Off-label: epidural or intrathecal administration for postoperative pain,Off-label: treatment of dyspnea in palliative care
Mild to moderate pain,Fever
0.8 to 10 mg via epidural injection as a single dose or via continuous epidural infusion at 0.1 to 1 mg/hour. For intrathecal use: 0.2 to 1 mg as a single dose. Intravenous: 2 to 10 mg for analgesia every 2-4 hours as needed.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life of morphine is approximately 2-4 hours in adults. In neonates and elderly, half-life may be prolonged (up to 4.5-6.5 hours). Context: half-life may be extended in renal impairment due to accumulation of active metabolites.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Primarily hepatic via glucuronidation by UGT2B7 to morphine-3-glucuronide (M3G, inactive) and morphine-6-glucuronide (M6G, active); minor metabolism via CYP2D6 to normorphine.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Primarily renal (approximately 90% as morphine-3-glucuronide and morphine-6-glucuronide, with 10% as unchanged morphine). Biliary/fecal excretion accounts for less than 10%.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
30-35% bound to albumin.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
3-5 L/kg (range 1-6 L/kg). Clinical meaning: indicates extensive tissue distribution.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Epidural/Intrathecal: effectively 100% at site of action (systemic bioavailability from epidural absorption is ~30-40% due to first-pass metabolism). Oral: 20-40% (not relevant for DURAMORPH PF).
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
GFR 50-90 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 25-50% and extend dosing interval; GFR <10 m L/min: avoid use or reduce dose by 50% and administer every 6-8 hours with close monitoring.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25-50% and monitor; Child-Pugh Class C: avoid use or reduce dose by 50% and extend dosing interval.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Epidural: 0.03 to 0.05 mg/kg as a single dose, may repeat every 4-6 hours; continuous infusion: 0.002 to 0.008 mg/kg/hour. Intrathecal: 0.01 to 0.02 mg/kg as a single dose. Intravenous: 0.05 to 0.1 mg/kg every 2-4 hours prn.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Reduce initial dose by 25-50% and titrate cautiously due to increased sensitivity and risk of respiratory depression. Use non-PVC tubing and avoid in renal impairment.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; NEONATAL OPIOID WITHDRAWAL SYNDROID; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS. Ensure proper patient selection, monitoring, and dispensing.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Risk of respiratory depression, especially in elderly, cachectic, or debilitated patients; central nervous system depression; serotonin syndrome with serotonergic drugs; adrenal insufficiency; hypotension; seizures; severe hypotension; use in patients with head injury; use in patients with biliary tract disease; use in patients with pancreatic disease; use in patients with renal impairment; use in patients with hepatic impairment; use in patients with respiratory conditions; use in patients with gastrointestinal obstruction; use in patients with prostatic hyperplasia; use in patients with urinary retention; use in patients with hypothyroidism; use in patients with adrenocortical insufficiency; use in patients with toxic psychosis; use in patients with alcoholism; use in patients with delirium tremens; use in patients with kyphoscoliosis; use in patients with severe obesity; use in patients with sleep apnea; use in patients with myxedema; use in patients with chronic obstructive pulmonary disease; use in patients with cor pulmonale; use in patients with respiratory depression; use in patients with acute or severe bronchial asthma; use in patients with paralytic ileus; use in patients with hypersensitivity to morphine; use in patients with gastrointestinal obstruction; weaning from opioids; physical dependence; withdrawal; tolerance; impaired mental or physical abilities; driving; operating machinery; risk of overdose; accidental ingestion; neonatal opioid withdrawal syndrome; concomitant use with alcohol; concomitant use with benzodiazepines; concomitant use with CNS depressants; abuse potential; monitoring; pregnancy; lactation; renal impairment; hepatic impairment; elderly; pediatric; recent intracranial surgery; increased intracranial pressure; impaired consciousness; coma; convulsive disorders; hypotension; hypovolemia; severe pulmonary disease; respiratory depression; sleep-related breathing disorders; drug dependence; misuse; addiction; abuse; diversion; storage and disposal.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity to morphine or any component of the formulation; significant respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction, including paralytic ileus; concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy; respiratory depression in the absence of resuscitative equipment; upper airway obstruction; status asthmaticus; severe chronic obstructive pulmonary disease; cor pulmonale; severe obesity; sleep apnea syndrome; myxedema; delirium tremens; acute alcoholism; increased intracranial pressure; head injury; intracranial lesions; impaired consciousness; coma; convulsive disorders; hypotension; hypovolemia; biliary tract surgery; suspected surgical abdomen; pancreatitis; prostatic hyperplasia; urethral stricture; urinary retention; use in pregnancy when premature delivery is anticipated; during labor when delivery of a premature infant is anticipated; during labor when narcotic antagonist is not available; use in breastfeeding; use in children less than 18 years (except as directed by a physician).
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Avoid alcohol and grapefruit juice for at least 24 hours after administration. Alcohol potentiates CNS depression and respiratory effects. No specific food restrictions beyond standard postoperative diet; however, patients should avoid large meals if nauseated. Maintain adequate fluid and fiber intake to mitigate constipation.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Preservative-free morphine (Duramorph PF) is FDA Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of neural tube defects and skeletal anomalies at high doses. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal opioid withdrawal syndrome (NOWS) after delivery. Not associated with major congenital malformations in human studies, but risk-benefit must be assessed.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Morphine is excreted into breast milk. M/P ratio is approximately 2.5. Relative infant dose is about 9-10% of maternal weight-adjusted dose. Use with caution; monitor for infant drowsiness, respiratory depression, and constipation. American Academy of Pediatrics considers morphine compatible with breastfeeding, but avoid during labor and delivery due to potential neonatal respiratory depression.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
No established dose adjustment guidelines for pregnancy. Pharmacokinetic changes: Increased volume of distribution and clearance in pregnancy may lower peak concentrations, but clinical significance is unclear. Use the lowest effective dose for the shortest duration. For epidural/intrathecal use, doses are typically adjusted by clinician based on maternal response and fetal status. Avoid high doses in third trimester due to risk of neonatal respiratory depression.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
DURAMORPH PF is a preservative-free morphine sulfate solution indicated for epidural or intrathecal administration. Onset of analgesia occurs within 10-15 minutes after epidural injection and peaks at 30-60 minutes; intrathecal onset is faster (5-10 minutes) with duration up to 24 hours. Due to risk of delayed respiratory depression, patients must be monitored in a setting equipped for resuscitation for at least 24 hours after administration. Naloxone should be readily available. Do not use if solution is discolored or contains precipitate. Avoid concurrent use with MAOIs or within 14 days of discontinuation.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
This medication is given directly into the spine to control severe pain. You will be closely monitored in the hospital. Report any trouble breathing, severe drowsiness, or itching.,Do not drive or operate machinery for at least 24 hours after administration. Avoid alcohol and sedatives, which may increase respiratory depression.,You may experience nausea, vomiting, constipation, or urinary retention. Notify your healthcare provider if these become severe.,If you have a history of opioid addiction, head injury, asthma, or kidney/liver disease, inform your doctor before treatment.,Do not breastfeed for 24 hours after receiving this medication. Inform all healthcare providers that you have received an intrathecal opioid.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DURAMORPH PF vs ACEPHEN, answered by our medical review team.
DURAMORPH PF is a Opioid Analgesic that works by Morphine is a full opioid agonist that primarily acts on mu-opioid receptors in the central nervous system to produce analgesia, euphoria, and sedation. It also interacts with kappa and delta receptors. It inhibits ascending pain pathways and alters pain perception and response.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DURAMORPH PF and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DURAMORPH PF is: 0.8 to 10 mg via epidural injection as a single dose or via continuous epidural infusion at 0.1 to 1 mg/hour. For intrathecal use: 0.2 to 1 mg as a single dose. Intravenous: 2 to 10 mg for analgesia every 2-4 hours as needed.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DURAMORPH PF and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DURAMORPH PF is classified as Category C. Preservative-free morphine (Duramorph PF) is FDA Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of neural tube defects and skeletal a. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.